China Medical Advances Vitiligo Treatment

China Medical System Holdings (HK:0867) has released an update.

China Medical System Holdings announced the acceptance of their New Drug Application for ruxolitinib phosphate cream, aimed at treating vitiligo, by China’s National Medical Products Administration. The cream showed significant efficacy in a Chinese Real-World Study, outperforming target values with mild to moderate adverse events. This product has potential to help the millions suffering from this chronic autoimmune skin condition in China and has already been made available in Hainan’s Pilot Zone and approved in Macau.

For further insights into HK:0867 stock, check out TipRanks’ Stock Analysis page.